Sinopharm Hyundai (600420.SH) subsidiary's injectable ceftazidime passed generic drug consistency evaluation

Zhitongcaijing · 04/15 08:17

Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Zhijun (Shenzhen) Pharmaceutical Co., Ltd. (hereinafter referred to as Sinopharm Zhijun), a holding subsidiary of the company, received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration to approve injectable ceftazidime (0.5g) to pass the consistent evaluation of generic drug quality and efficacy.

Ceftazidime is a third-generation cephalosporin antibiotic. It is suitable for treating severe systemic infections caused by sensitive bacteria, lower respiratory infections (including pneumonia), ear, nose and throat infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, gynecological infections, gastrointestinal, biliary, and abdominal infections, blood/peritoneal dialysis, and continuous non-invasive peritoneal dialysis (CAPD) related infections, central nervous system infections (including meningitis), and preventing perioperative urinary tract infections.